years, though it recently sought new public input on its CED guidance document. “I’m seeing big players in industry … make public comments that CED is good for innovation,” he said. Jacques also would like to see CED have greater breadth and flexibility so that not every new molecular indicator and LDT needs to be reviewed.
Medicare still has considerable local authority, Jacques pointed out, and local decisions do not necessarily apply nationwide. More collaborative review processes could help create greater nationwide consistency.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine "
6 Regulation, Reimbursement, and Public Health ."
Genome-Based Diagnostics: Clarifying Pathways to Clinical Use: Workshop Summary . Washington, DC: The National Academies Press,
Please select a format: